Talati Naasha J, Seybold Ulrich, Humphrey Bianca, Aina Abiola, Tapia Jane, Weinfurter Paul, Albalak Rachel, Blumberg Henry M
Division of Infectious Diseases, Emory University, School of Medicine, Atlanta, GA, USA.
BMC Infect Dis. 2009 Feb 10;9:15. doi: 10.1186/1471-2334-9-15.
A new generation of diagnostic tests, the interferon-gamma release assays (IGRAs), have been developed for the detection of latent tuberculosis infection (LTBI). Limited data are available on their use in HIV-infected persons.
A cross-sectional study was carried out at 2 HIV clinics in Atlanta to assess the utility of two IGRA tests (T-SPOT.TB [TSPOT] and QuantiFERON-TB Gold in Tube [QFT-3G]) compared to the tuberculin skin test (TST).
336 HIV-infected persons were enrolled. Median CD4 count was 335 cells/microl and median HIV viral load was 400 copies/ml. Overall, 27 patients (8.0%) had at least 1 positive diagnostic test for LTBI: 7 (2.1%) had a positive TST; 9 (2.7%) a positive QFT-3G; and 14 (4.2%) a positive TSPOT. Agreement between the 3 diagnostic tests was poor: TST and TSPOT, [kappa = 0.16, 95% CI (-0.06, 0.39)], TST and QFT-3G [kappa = 0.23, 95% CI (-0.05, 0.51)], QFT-3G and TSPOT [kappa = 0.06, 95% CI (-0.1, 0.2)]. An indeterminate test result occurred among 6 (1.8%) of QFT-3G and 47 (14%) of TSPOT tests. In multivariate analysis, patients with a CD4 < or = 200 cells/microl were significantly more likely to have an indeterminate result [OR = 3.6, 95% CI (1.9, 6.8)].
We found a low prevalence of LTBI and poor concordance between all 3 diagnostic tests. Indeterminate test results were more likely at CD4 counts < or = 200 cells/microl. Additional studies among HIV-infected populations with a high prevalence of TB are needed to further assess the utility of IGRAs in this patient population.
新一代诊断测试,即干扰素-γ释放试验(IGRAs),已被开发用于检测潜伏性结核感染(LTBI)。关于其在HIV感染者中的应用的数据有限。
在亚特兰大的两家HIV诊所进行了一项横断面研究,以评估两种IGRA测试(T-SPOT.TB [TSPOT]和管内QuantiFERON-TB Gold [QFT-3G])与结核菌素皮肤试验(TST)相比的效用。
招募了336名HIV感染者。CD4细胞计数中位数为335个/微升,HIV病毒载量中位数为400拷贝/毫升。总体而言,27名患者(8.0%)至少有1项LTBI诊断测试呈阳性:7名(2.1%)TST呈阳性;9名(2.7%)QFT-3G呈阳性;14名(4.2%)TSPOT呈阳性。这3种诊断测试之间的一致性较差:TST和TSPOT,[kappa = 0.16,95%可信区间(-0.06,0.39)],TST和QFT-3G [kappa = 0.23,95%可信区间(-0.05,0.51)],QFT-3G和TSPOT [kappa = 0.06,95%可信区间(-0.1,0.2)]。QFT-3G测试中有6名(1.8%)出现不确定的测试结果,TSPOT测试中有47名(14%)出现不确定的测试结果。在多变量分析中,CD4≤200个/微升的患者出现不确定结果的可能性显著更高[比值比 = 3.6,95%可信区间(1.9,6.8)]。
我们发现LTBI的患病率较低,且所有3种诊断测试之间的一致性较差。CD4细胞计数≤200个/微升时,出现不确定测试结果的可能性更大。需要在结核病患病率高的HIV感染人群中进行更多研究,以进一步评估IGRAs在该患者群体中的效用。